Every 8-K that Lixte Biotechnology Holdings, Inc. Warrants (LIXTW) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow LIXTW and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full LIXTW filings page.
Lixte Biotechnology Holdings, Inc. completed a registered direct offering of 2,366,503 shares of common stock and Pre-Funded Warrants to purchase 258,859 shares, generating gross proceeds of approximately $16.6 million before expenses. The securities were priced at $6.31 per share of common stock and $6.30 per Pre-Funded Warrant.
The Pre-Funded Warrants are immediately exercisable at $0.0001 per share and remain exercisable until fully exercised. The transaction, conducted under an effective shelf registration statement on Form S-3, closed on June 4, 2026, and the company plans to use the net proceeds for general corporate purposes and working capital.
LIXTE Biotechnology Holdings is undertaking a major strategic shift, repositioning itself as an AI energy infrastructure equipment and services platform focused on supplying power solutions for AI and hyperscale data centers. The company highlights a widening gap between North American electricity demand and generation capacity, citing a projected 224 gigawatt increase in summer peak demand over the next decade and recent reliability alerts to frame the opportunity.
As part of this transformation, LIXTE plans to seek a strategic acquisition partner for its clinical-stage pharmaceutical and med-tech operations that are developing cancer therapies and proton therapy systems. The company expects to maintain its Nasdaq listing under the symbol LIXT while it executes this pivot and pursues strategic acquisitions and partnerships in advanced generation technologies.
LIXTE also appointed Stuart D. Porter to its Board of Directors, effective May 29, 2026, with a term expiring at the 2026 annual meeting. Porter is the Founder, Managing Partner, Chief Executive Officer and Chief Investment Officer of Denham Capital, with over 29 years of senior investment experience and oversight of more than $12 billion of invested and committed capital across energy and energy-transition sectors, including a roughly 10 gigawatt pipeline of AI data-center-oriented power generation opportunities.
Lixte Biotechnology Holdings, Inc. updated its executive compensation by amending the employment agreement of Chief Executive Officer Geordan Pursglove. Effective January 1, 2026, his annual base salary increased from $240,000 to $360,000, as approved by the Compensation Committee and Board of Directors. The salary Amendment, dated March 18, 2026, is filed as Exhibit 10.1 and incorporated by reference into this report.
Lixte Biotechnology Holdings entered into an Amended and Restated Share Exchange Agreement with its subsidiary Liora Technologies Europe and Orbit Capital, dated March 6, 2026 and effective as of November 21, 2025. This agreement consolidates prior arrangements into a single structure.
Under earlier agreements, Lixte had acquired 100% of Liora, issued 2,700 shares of Series C Preferred Stock to Orbit and entered a royalty agreement, which was later terminated. Orbit then exchanged those preferred shares for 700,000 shares of Lixte common stock and reacquired a 20% ownership interest in Liora. The new agreement is intended to reflect these combined transactions and the parties’ agreed ownership structure.
LIXTE Biotechnology Holdings, Inc. entered into an Allocation Deed and a Consultancy Agreement with its subsidiary Liora Technologies Europe Ltd. and consultant Sidney Braun. Braun becomes CEO and a director of Liora, with a GBP 50,000 signing bonus and a GBP 25,000 monthly retainer, both exclusive of VAT.
Under the Allocation Deed, Braun is entitled to 20% of the net purchase price if there is a sale of Liora or any Liora successor. LIXTE also issued a press release highlighting Braun’s healthcare background and Liora’s LiGHT System proton therapy technology for cancer treatment.
Lixte Biotechnology Holdings, Inc. filed a current report describing a recent treasury move into digital assets. On September 10, 2025, the company issued a press release announcing an initial purchase of digital currency totaling $2.6 million.
The disclosure is furnished under Regulation FD, meaning it is provided for informational purposes and is not treated as filed financial information under securities laws. The report also includes standard forward-looking statement cautions about risks and uncertainties that could cause actual results to differ from expectations.
Form 8-K – Item 8.01 (Other Events) filed 11 July 2025 discloses that Lixte Biotechnology Holdings, Inc. (NASDAQ: LIXT; warrants LIXTW) issued a 9 July 2025 press release announcing that Nature has published independent research findings that support the scientific rationale underlying the Company’s ongoing Phase II studies in ovarian and colorectal cancers. The Company states that the peer-reviewed article, authored by external physician-scientists, validates the biochemical mechanism targeted by Lixte’s lead compound, thereby reinforcing its clinical development strategy.
There are no financial statements, earnings metrics or transaction details in this filing; the sole purpose is to place the Nature publication on the public record. Management believes the publication may enhance trial enrollment, attract potential partners and improve the Company’s credibility with investors and clinicians, but it does not change the risk profile inherent in early-stage oncology drug development.
- Event date: 9 July 2025 (filed 11 July 2025)
- Affected programs: Ovarian & colorectal cancer trials
- Regulatory status: Unchanged – trials continue; no new FDA submission
- Financial impact: Not quantified; no revenue guidance updated
Overall, the filing is a positive scientific milestone rather than a material financial event, but peer-review validation in a top-tier journal may incrementally strengthen the investment thesis for Lixte’s pipeline.
Lixte Biotechnology Holdings, Inc. (NASDAQ: LIXT) filed an 8-K reporting that it entered into a Securities Purchase Agreement on 3 July 2025 for a registered direct offering that closed on 8 July 2025.
Transaction terms: the company sold 210,675 common shares and pre-funded warrants covering 763,351 shares at an offering price of $1.54 per share (or $1.53999 per warrant), generating gross proceeds of approximately $1.5 million before deductions.
Placement agent: Spartan Capital Securities, LLC acted as exclusive placement agent, earning a cash fee equal to 8 % of gross proceeds and reimbursement of $40,000 in legal fees under a separate Placement Agent Agreement.
Exhibits: the filing includes the Form of Pre-Funded Warrant (4.1), legal opinion from TroyGould PC (5.1), Securities Purchase Agreement (10.1), Placement Agent Agreement (10.2) and the related press release (99.1).
The report emphasizes that the agreements’ representations and warranties are made solely between the contracting parties and may employ materiality standards different from those of public investors.